Advances in Chronic Kidney Disease
Volume 13, Issue 1 , Pages 62-69, January 2006

Special Issues in Pediatric Kidney Transplantation

  • Alicia M. Neu

      Affiliations

    • Corresponding Author InformationAddress correspondence to Alicia M. Neu, MD, The Johns Hopkins University School of Medicine, 600 North Wolfe Street, Park 335, Baltimore, MD 21287.

Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD.

Pediatric and adult kidney transplantation differ in many ways, but one of the most significant differences is the impact of kidney disease and kidney transplantation on growth and development in pediatric patients. Multiple facets of transplantation may have an impact on growth and development, including the timing of transplantation, choice of immunosuppressive agents, and the presence of hypertension. In addition, graft function has a significant impact on linear growth, and so preservation of function becomes important not only for general health and quality of life but also for optimizing growth. Other concerns in pediatric kidney transplantation include a heightened risk for posttransplantation infectious complications, including lymphoproliferative disease. In addition, the impact of immunosuppressive drugs on adherence to therapy is important. Although adherence is a complex and multifactorial process, immunosuppressive drugs that cause physical side effects may contribute to drug nonadherence because children, and particularly adolescents, may be inclined to stop taking medications associated with physical changes that differentiate them from their peers. Studies that further delineate factors that affect growth and development, risk for infectious complications, and nonadherence will be important to maximize outcomes in pediatric kidney transplantation.

Index Words:  Kidney , transplant , pediatric

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Dr. Neu has received unrestricted educational grants from and had a speaker’s agreement with Fujisawa Pharmaceutical Company, Ltd, now Astellas Pharma US, Inc.

PII: S1548-5595(05)00193-X

doi:10.1053/j.ackd.2005.10.001

Advances in Chronic Kidney Disease
Volume 13, Issue 1 , Pages 62-69, January 2006